TreviLogo.png
Trevi Therapeutics to Present at BTIG Virtual Biotechnology Conference
August 05, 2020 07:30 ET | Trevi Therapeutics
NEW HAVEN, Conn., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™...
TreviLogo.png
Trevi Therapeutics to Present at BMO Prescriptions for Success Healthcare Virtual Conference
June 17, 2020 16:05 ET | Trevi Therapeutics
NEW HAVEN, Conn., June 17, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
TreviLogo.png
Trevi Therapeutics to Hold Virtual 2020 Annual Meeting of Stockholders
May 29, 2020 16:05 ET | Trevi Therapeutics
NEW HAVEN, Conn., May 29, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
TreviLogo.png
Trevi Therapeutics Announces First Quarter 2020 Financial Results and Corporate Update
May 07, 2020 16:05 ET | Trevi Therapeutics
Sample Size Re-Estimation Analysis for PRISM Trial Expected in Mid-2020 New Patient Screening Re-Starting at PRISM Sites in the US and Europe Cash Position of $52.6 Million Expected to Fund...
TreviLogo.png
TREVI THERAPEUTICS TO PRESENT AT NEEDHAM HEALTHCARE CONFERENCE
April 08, 2020 16:05 ET | Trevi Therapeutics
NEW HAVEN, Conn., April 08, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of...
TreviLogo.png
TREVI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND YEAR END 2019 FINANCIAL RESULTS AND CORPORATE UPDATE
March 16, 2020 08:00 ET | Trevi Therapeutics
Enrollment in PRISM Study Progressing - Sample Size Re-estimation Planned for mid-2020 Expect to Report Top-Line Data in both PN and IPF-Cough Trials in Second Half of 2020 Cash Position of $57.3...
TreviLogo.png
Trevi Therapeutics to Present at SVB Leerink Healthcare Conference
February 20, 2020 16:05 ET | Trevi Therapeutics
NEW HAVEN, Conn., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...
TreviLogo.png
Trevi Therapeutics Announces Election of James V. Cassella, Ph.D. to Board of Directors
February 18, 2020 16:05 ET | Trevi Therapeutics
NEW HAVEN, Conn., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (“Trevi”), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine ER...
TreviLogo.png
Trevi Therapeutics Announces Third Quarter 2019 Financial Results and Recent Business Developments
November 14, 2019 16:05 ET | Trevi Therapeutics
Advancement of Nalbuphine ER in Clinical Development for Three Indications Cash Position of $63.5 Million Expected to Fund Operations Through At Least Q1 2021 NEW HAVEN, Conn., Nov. 14, 2019 ...
TreviLogo.png
Trevi Therapeutics to Present at Stifel Healthcare Conference
November 13, 2019 17:01 ET | Trevi Therapeutics
NEW HAVEN, Conn., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of nalbuphine...